首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   59篇
  免费   0篇
儿科学   1篇
基础医学   2篇
口腔科学   1篇
临床医学   2篇
内科学   11篇
神经病学   1篇
特种医学   39篇
药学   2篇
  2023年   1篇
  2015年   1篇
  2013年   2篇
  2007年   1篇
  2006年   3篇
  2005年   1篇
  2004年   2篇
  2003年   1篇
  2002年   2篇
  2001年   1篇
  2000年   1篇
  1998年   1篇
  1996年   1篇
  1969年   1篇
  1964年   1篇
  1943年   3篇
  1941年   9篇
  1940年   5篇
  1937年   2篇
  1936年   2篇
  1935年   3篇
  1934年   1篇
  1933年   6篇
  1932年   1篇
  1931年   4篇
  1930年   1篇
  1928年   2篇
排序方式: 共有59条查询结果,搜索用时 15 毫秒
11.
12.
13.
14.
15.
16.
Hanefeld C  Sirtl C  Spiecker M  Bojara W  Grewe PH  Lawo T  Mügge A 《Chest》2004,126(3):935-941
STUDY OBJECTIVES: To assess the practical application and safety of prehospital antithrombotic therapy with the glycoprotein (GP) IIb/IIIa inhibitor eptifibatide for patients with suspected acute coronary syndrome (ACS) or myocardial infarction (MI). DESIGN: Open-labeled pilot study. Patients with typical chest pain who were seen within 6 h of the onset of symptoms were enrolled in the mobile emergency ambulance. Patients were stratified by even/uneven days to receive standard treatment or standard treatment plus an IV bolus of eptifibatide (180 microg/kg body weight) followed by a continuous eptifibatide infusion (2 microg/kg/min). The main outcome measurement was a combination of prehospital or in-hospital death, reinfarction, revascularization of target vessels, and major bleeding complications. RESULTS: A total of 356 patients (age range, 29 to 75 years; women, 24.7%) were included in the analysis. On admission to the hospital, the diagnosis of ACS or MI was confirmed in approximately 60% of patients, and alternative diagnoses were made in 40% of patients. The rates of complications, including fatal and nonfatal complications occurring during transportation and during subsequent hospitalization, were similar in both study groups. The primary end point occurred in 11.8% of patients in the control group, and in 9.6% of those in the eptifibatide group (difference not significant). CONCLUSION: The prehospital administration of the GP IIb/IIIa inhibitor eptifibatide is feasible and safe in patients with clinically suspected ACS and MI. The benefit of this treatment has yet to be established in a large-scale multicenter study.  相似文献   
17.
18.
19.
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号